Annual Report

Overview

The report records 4.2% year-on-year growth in domestic prescription-drug sales alongside higher Crestor royalty income, and consolidated net sales of ¥282,350 million. It highlights global Phase III development of anti-HIV candidate S-349572 and progress on other pipeline compounds. It also describes restoring Kanegasaki Plant production about a month after the March 2011 earthquake, alongside the company's CSR and environmental programs.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2010-2011
Period: 1 April 2010 – 31 March 2011
Language: English
Pages
File size

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services